Another study demonstrated that Anti-CD20–IFNα fusion protein was more effective than anti-CD20 Ab alone for direct killing of type IFNα receptor (IFNAR)-positive lymphoma (Xuan et al.2010). The gene discussed is IFNA1; the disease is lymphoma.